ClinicalTrials.gg
RecruitingNCT07200089Updated Oct 15, 2026

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

A Phase 1 interventional study of NT-I7 and Placebo in Multiple Myeloma, Multiple Myeloma in Relapse and Multiple Myeloma, Refractory, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 15, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Multiple Myeloma by Washington University School of Medicine — 7 open to participants now, 11 under way, none of them phase 3. Multiple Myeloma · Washington University School of Medicine.

Planned enrollment
9th of 38
52 · median 21
Started
2026
with 1 other
Phase 1
17 of 40
4 open now
Primary completion
2028-03
later than 7 of 10 live
Registered
38th of 40
by date

Among the 40 studies in Multiple Myeloma by Washington University School of Medicine, this one is the 9th largest by planned enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 in phase 1, reaches primary completion later than 7 of the 10 other live ones, and was the 38th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

7 of the 40 studies in Multiple Myeloma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by Washington University School of Medicine, or all of them as a file.
02

Study summary

CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation Antigen (BCMA). While BCMA CAR-T cell-treated patients achieve an excellent overall response rate, their response is often not durable. NT-I7 promotes CAR-T cell expansion and efficacy in pre-clinical lymphoma models. In patients receiving CD19-directed CAR-T therapy for lymphoma, NT-I7 augmented CAR-T expansion while being safe and tolerable. The impact of NT-I7 on BCMA CAR-T cells in multiple myeloma is unknown.

This is a two-stage, multicenter, phase IB study, with a dose escalation stage leading into a two-arm, double blind, placebo-controlled, randomized dose expansion stage testing the safety and toxicity of adding NT-I7 to BCMA CAR-T therapy in patients with relapsed and refractory multiple myeloma. The hypothesis is that NT-I7 will promote CAR-T expansion and persistence which will enhance clearance of MM, while maintaining a favorable safety and toxicity profile. Patients receiving standard of care BCMA CAR-T (cilta-cel) will be randomized to either NT-I7 or placebo. Correlative studies will evaluate CAR-T cell expansion, persistence, immune-phenotype, function and correlate with clinical outcomes.

03

Conditions studied

  • Multiple Myeloma
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory

Browse trials for

Keywords

  • Cytokines
  • Interleukin-7
  • Cellular therapy
  • Chimeric antigen receptor T cell therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma with by IMWG criteria.
  • Eligible for standard of care, FDA-approved BCMA CAR-T cell therapy with ciltacabtagene autoleucel.

    • Patients enrolling in the dose escalation stage must have received at least two and be penta-drug exposed (i.e. exposure to at least 5 active anti-myeloma drugs, excluding and melphalan and including, at minimum, a proteasome inhibitor, an immunomodulatory drug, and a CD38 monoclonal antibody).
  • ≥ 12 weeks per assessment from the enrolling physician.
  • At least 18 years of age.
  • performance status ≤ 2
  • Adequate organ function as defined below:

    • Total ≤ 1.5 x IULN
    • (SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • > 30 mL/min by Cockcroft-Gault
  • The effects of NT-I7 on the developing human fetus are unknown. For this reason, women of and men must agree to use adequate prior to study entry until 90 days after completion of NT-I7 therapy/placebo (corresponding to Day 125 post CAR-T). Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s/he must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Received prior BCMA-directed therapy.
  • Prior or concurrent whose natural history has the potential to interfere with the safety or efficacy assessment of the regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.
  • Currently receiving or have received any other investigational agents within 14 days prior to CAR-T infusion.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to NT-I7or other agents used in the study.
  • Uncontrolled intercurrent illness including but not limited to: ongoing or active infection (bacterial, fungal, viral, or tuberculosis, including known hepatitis A, B, or C, or (testing not required)), symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia (except well-controlled atrial fibrillation). Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Function Classification; to be eligible for this trial, patients should be a class 2B or better.
  • Pregnant and/or breastfeeding. Women of must have a negative serum pregnancy test within 14 days prior to starting CAR-T therapy.
  • Receipt of live, attenuated vaccine within 30 days prior to first day of treatment.
  • Had an allogeneic tissue/solid organ transplant or stem cell transplant.
  • Not able to receive intramuscular therapy.
  • Prior history of T cell malignancy.
  • Prior history of congenital immunodeficiency syndrome.
  • Prior history of disease with significant disease activity in the past 2 years, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, Sézary syndrome, vasculitis or glomerulonephritis, Bell's palsy, Guillain-Barré syndrome, or multiple sclerosis.
  • Prior history of plasma cell leukemia, systemic amyloidosis, POEMS syndrome, or multiple myeloma with CNS involvement.
  • Planning to start maintenance therapy prior to Day 100 post-CAR-T therapy.
  • A history of pulmonary disorders, such as severe asthma, severe , restrictive lung disease, symptomatic pulmonary embolism within 3 months prior to study enrollment, or active or prior interstitial lung disease/pneumonitis.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Dose Level -1: NT-I7

    Patients will receive 480 μg/kg NT-I7 intramuscularly on Day 14 and a second dose on Day 35.

    Drug: NT-I7

  • Experimental
    Dose Escalation Dose Level 1 (Starting Dose): NT-I7

    Patients will receive 600 μg/kg NT-I7 intramuscularly on Day 14 and a second dose on Day 35.

    Drug: NT-I7

  • Experimental
    Dose Escalation Dose Level 2: NT-I7

    Patients will receive 720 μg/kg NT-I7 intramuscularly on Day 14 and a second dose on Day 35.

    Drug: NT-I7

  • Experimental
    Dose Expansion: NT-I7

    Patients randomized to the intervention arm will receive the recommended phase II dose of NT-I7 intramuscularly on Day 14 and a second dose on Day 35.

    Drug: NT-I7

  • Sham comparator
    Dose Expansion: Placebo

    Patients randomized to the control arm will receive a placebo on Days 14 and 35.

    Drug: Placebo

Interventions

  • DrugEfineptakin alfaStudies of Efineptakin alfaEfineptakin alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    NT-I7 will be supplied by NeoImmuneTech Inc

    Also known as: Recombinant human IL-7, Efineptakin alfa

  • DrugPlacebo

    Placebo will be supplied by NeoImmuneTech Inc

06

What researchers measure

Primary outcomes

  1. Rate of non-hematologic grade ≥3 treatment-related adverse events (excluding expected conditioning-related AEs)

    Graded per CTCAE v 5.0.

    Time frame: From Day 14 to Day 100

  2. Recommended phase II dose (Dose escalation stage only)

    The recommended phase II dose (RP2D) is defined as the highest tested dose level or the dose level immediately below the dose level at which 2 or more patients experience dose-limiting toxicity during the dose-limiting toxicity (DLT) assessment period.

    Time frame: Through day 65 for all dose escalation stage patients (estimated to be 3 months and 65 days)

Secondary outcomes

  1. MRD negativity by clonoSEQ (10^5 cutoff)

    Time frame: At Day 100

  2. MRD negativity by clonoSEQ (10^6 cutoff)

    Time frame: At Day 100

  3. Number of participants with stringent complete response (sCR) by IMWG criteria

    * Stringent complete response requires all of the following: * CR as defined below * Normal free light chain ratio (0.26-1.65) * Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence * Complete response (CR) requires all of the following: * Negative immunofixation on the serum and urine * \<5% plasma cells in the bone marrow aspirate * Disappearance of any soft tissue plasmacytomas * Normalization of the serum free light chain ratio in patients who lack measurable M protein in the serum and urine at baseline

    Time frame: At Day 100

  4. Progression-free survival (PFS)

    * PFS is defined as the length of time between randomization and disease progression or death from any cause. * Progressive disease per IMWG criteria.

    Time frame: At Day 365

  5. Number of participants with Grade ≥2 CRS and ICANS according to ASTCT consensus grading

    Time frame: From Day 0 through Day 100

  6. Number of participants with Grade ≥3 CRS and ICANS according to ASTCT consensus grading

    Time frame: From Day 0 through Day 100

  7. Rate of non-relapse mortality (NRM)

    For the purposes of this study, NRM is death following CAR-T cell infusion without evidence of progressive myeloma.

    Time frame: By Day 365

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Michael Slade, M.D., M.S.C.I · Contactsladem@wustl.edu · 314-454-8304
    • Michael Slade, M.D., M.S.C.I · Principal investigator
    • Arun Cumpelik, M.D. · Sub investigator
    • John F DiPersio, M.D., Ph.D. · Sub investigator
    • Feng Gao, M.D., Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified patient level data may be shared following publication of the manuscript analyzing the primary endpoint of this study.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Up to 5 years following trial completion.

Access criteria: Interested researchers seeking access to de-identified data related to this trial should contact the principal investigator at sladem@wustl.edu. Requests will be considered on a case-by-case basis.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

Of 201 non-industry phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 99. This study's planned 21 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Jun 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 30, 2025
StartActual
Jun 5, 2026was Aug 2026
Primary completionEst.
Mar 10, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 31, 2026→Jun 5, 2026 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Start date Aug 31, 2026→Jun 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07200089
Collaborators
NeoImmuneTech, Swim Across America
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Jun 5, 2026
Primary completion
Mar 10, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 15, 2026

Study contacts

Michael Slade, M.D., M.S.C.I.
Contact
sladem@wustl.edu
314-454-8304
Michael Slade, M.D., M.S.C.I
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efineptakin alfa

Start the discussion